Amaya Gascó, M.D., Ph.D. joined Kura Oncology in August 2022 as Vice President, Clinical Development with early-to-late Oncology drug development experience and more than 15 years’ experience as a medical oncologist, predominately focused on lung and gastrointestinal cancers. Prior to Kura, she served in roles of increasing responsibility at AstraZeneca as part of the Local and Global Medical Affairs teams and R&D early and late-stage development departments. Most recently she held the position of Global Clinical Program Lead in R&D Oncology, Late Development, where she led the design, delivery and interpretation of the T-Dxd (Enhertu) clinical lung cancer studies from phase I to phase III.
Earlier to her career in the biopharmaceutical industry, Dr. Gascó worked as a medical oncologist from 2006 to 2014, and during the latter years, she was actively involved in translational and clinical research projects across various oncology indications.
Dr. Gascó obtained her undergraduate degree from Rovira I Virgili University in Reus, Spain and completed her specialized training in medical oncology at the University Hospital Del Mar in Barcelona, Spain. She holds a PhD. in Medicine, focused on translational oncology, graduating summa cum laude from the Autonomous University of Barcelona.